{
    "nct_id": "NCT02257242",
    "official_title": "BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (MarqiboÂ®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma",
    "inclusion_criteria": "* Histologically confirmed indolent B-cell non-Hodgkin lymphoma.\n* Radiological measurable disease.\n* Previous treatment for lymphoma is allowed, with the exception of use of bendamustine within 6 months or any prior use of vincristine sulfate liposome injection\n* Eastern Cooperative Oncology Group performance status 0 or 1;\n* Life expectancy of at least 6 months;\n* Adequate organ and marrow function;\n* Women of child-bearing potential and men must agree to use adequate contraception.\n* Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of allergic reactions attributed to any drug used in the study.\n* Any lymphoma-directed therapy within 4 weeks.\n* Any prior treatment with vincristine sulfate liposome injection.\n* Prior treatment with bendamustine or vincristine sulfate within 180 days of enrollment.\n* Patients who are receiving any other investigational agents with the exception of endocrine therapy for breast or prostate cancer.\n* Central nervous system involvement.\n* Peripheral sensory or motor neuropathy.\n* History of a demyelinating condition.\n* Positive test for the Human Anti-Chimeric Antibody (HACA).\n* Patients receiving any medications or substances that are strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzyme are ineligible.\n* Uncontrolled intercurrent illness.\n* Prisoners.\n* Pregnant or breast-feeding women.\n* Known Human Immunodeficiency Virus (HIV) or active Hepatitis B infection\n* Any prior or active cancer, which in the opinion of the investigator would preclude safe participation in this study.",
    "miscellaneous_criteria": ""
}